Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Fumiaki Uehara is active.

Publication


Featured researches published by Fumiaki Uehara.


Bioorganic & Medicinal Chemistry Letters | 2013

6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors.

Fumiaki Uehara; Aya Shoda; Keiichi Aritomo; Kenji Fukunaga; Kazutoshi Watanabe; Ryoichi Ando; Masaki Shinoda; Hiroaki Ueno; Hideo Kubodera; Shinji Sunada; Kenichi Saito; Takahide Kaji; Shoichi Asano; Jun-ichi Eguchi; Satoshi Yuki; Shinji Tanaka; Yukimi Yoneyama

The discovery of a series of 6-(4-pyridyl)pyrimidin-4(3H)-ones derived from a hit compound with low molecular weight and sufficient chemical space is reported. Transformation of substituents led to subnanomolar potent inhibitors with in vivo tau phoshorylation lowering activity.


Bioorganic & Medicinal Chemistry Letters | 2013

2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; A new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors

Kenji Fukunaga; Fumiaki Uehara; Keiichi Aritomo; Aya Shoda; Shinsuke Hiki; Masahiro Okuyama; Yoshihiro Usui; Kazutoshi Watanabe; Koichi Yamakoshi; Toshiyuki Kohara; Tokushi Hanano; Hiroshi Tanaka; Susumu Tsuchiya; Shinji Sunada; Kenichi Saito; Jun-ichi Eguchi; Satoshi Yuki; Shoichi Asano; Shinji Tanaka; Akiko Mori; Keiji Yamagami; Hiroshi Baba; Takashi Horikawa; Masatake Fujimura

A series of 2-(2-phenylmorpholin-4-yl)pyrimidin-4(3H)-ones was synthesized and examined for their inhibitory activity against glycogen synthase kinase-3β (GSK-3β). We found 21, 29 and 30 to possess potent in vitro GSK-3β inhibitory activity with good in vitro PK profiles. 21 demonstrated significant decrease of tau phosphorylation after oral administration in mice and excellent PK profiles.


Bioorganic & Medicinal Chemistry Letters | 2014

Asymmetric synthesis of 2-arylpiperazines

Satoshi Yokoshima; Kazutoshi Watanabe; Fumiaki Uehara; Yoshihiro Usui; Hiroshi Tanaka

An asymmetric synthesis of 2-arylpiperazines starting from phenacyl bromides, a variety of which are easily available, has been established. The synthesis features a CBS reduction of phenacyl bromide to provide optically enriched compounds, an SN2 reaction of 1,2,3-oxathiazolidine 2-oxides with an azide anion with invert of configuration, and construction of the piperazine ring via reduction of piperazine-2,3-diones.


Bioorganic & Medicinal Chemistry Letters | 2017

Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors

Yoshihiro Usui; Fumiaki Uehara; Shinsuke Hiki; Kazutoshi Watanabe; Hiroshi Tanaka; Aya Shouda; Satoshi Yokoshima; Keiichi Aritomo; Takashi Adachi; Kenji Fukunaga; Shinji Sunada; Mika Nabeno; Kenichi Saito; Jun-ichi Eguchi; Keiji Yamagami; Shouichi Asano; Shinji Tanaka; Satoshi Yuki; Narihiko Yoshii; Masatake Fujimura; Takashi Horikawa

We herein describe the results of further evolution of glycogen synthase kinase (GSK)-3β inhibitors from our promising compounds containing a 2-phenylmorpholine moiety. Transformation of the morpholine moiety into a piperazine moiety resulted in potent GSK-3β inhibitors. SAR studies focused on the phenyl moiety revealed that a 4-fluoro-2-methoxy group afforded potent inhibitory activity toward GSK-3β. Based on docking studies, new hydrogen bonding between the nitrogen atom of the piperazine moiety and the oxygen atom of the main chain of Gln185 has been indicated, which may contribute to increased activity compared with that of the corresponding phenylmorpholine analogues. Effect of the stereochemistry of the phenylpiperazine moiety is also discussed.


Archive | 2002

3-substituted-4-pyrimidone derivatives

Fumiaki Uehara; Keiichi Aritomo; Aya Shoda; Shinsuke Hiki; Masahiro Okuyama; Yoshihiro Usui; Mitsuru Ooizumi; Kazutoshi Watanabe


Archive | 2004

2,3,6-trisubstituted-4-pyrimidone derivatives

Kazutoshi Watanabe; Fumiaki Uehara; Shinsuke Hiki; Satoshi Yokoshima; Yoshihiro Usui; Masahiro Okuyama; Aya Shoda; Keiichi Aritomo; Toshiyuki Kohara; Kenji Fukunaga


Archive | 2001

2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives

Garcia Antonio Almario; Ryoichi Ando; Keiichi Aritomo; Jonathan Reid Frost; Adrien Tak Li; Aya Shoda; Fumiaki Uehara; Kazutoshi Watanabe


Archive | 2005

2-MORPHOLINO-4-PYRIMIDONE COMPOUND

Kazutoshi Watanabe; Fumiaki Uehara; Shinsuke Hiki; Toshiyuki Kohara; Kenji Fukunaga; Satoshi Yokoshima


Archive | 2007

2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors

Kenji Fukunaga; Toshiyuki Kohara; Kazutoshi Watanabe; Yoshihiro Usui; Fumiaki Uehara; Satoshi Yokoshima; Daiki Sakai; Shin-ichi Kusaka; Kazuki Nakayama


Archive | 2006

Intermediate compound for synthesizing pharmaceutical agent and production method thereof

Masahiro Okuyama; Fumiaki Uehara; Hiroshi Iwamura; Kazutoshi Watanabe

Collaboration


Dive into the Fumiaki Uehara's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Aya Shoda

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kenji Fukunaga

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar

Shinsuke Hiki

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yoshihiro Usui

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge